Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Short stature is one of the main reasons for consultation in outpatient clinics and paediatric endocrinology departments and is defined as height below the 3rd centile or less than -2 standard deviations (SDs).

Material And Methods: The study's overarching aim was to analyse the PAPP-A2 gene at mutation sites described to date and at exons 3, 4, and 5, which encode the fragment of the catalytic domain with the active site of the pregnancy-associated plasma protein A2 (PAPP-A2) protein. The secondary aims of the study were clinical and auxological analysis of a group of patients with idiopathic short stature and biochemical analysis of growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis parameters not assessed as part of the routine diagnosis of short stature, such as free IGF-1, insulin-like growth factor binding protein 5 (IGFBP-5), and acid-labile subunit (ALS) levels. Molecular analysis of the PAPP-A2 gene was performed using polymerase chain reaction (PCR) and direct sequencing. Biochemical analysis of free IGF-1, IGFBP-5, and ALS was performed by enzyme-linked immunosorbent assay (ELISA).

Results: The mean height standard deviation score (HSDS) in the study group was -2.95. None of the patients exhibited previously described mutations in the PAPP-A2 gene or mutations in exons 3, 4, and 5 encoding the fragment of catalytic domain with the active site of the PAPP-A2 protein. In 4 patients, the known, non-pathogenic, heterozygotic polymorphism c.2328C>T(rs10913241) in exon 5 was found.

Conclusions: Free IGF-1 levels correlate better with height and HSDS than total IGF-1 levels. The previously described mutations in the PAPP-A2 gene and mutations in exons 3, 4, and 5 encoding the fragment of catalytic domain with the active site of the PAPP-A2 protein were not detected; only the known and non-pathogenic, heterozygotic polymorphism c.2328C>T(rs10913241) in exon 5 of the PAPP-A2 gene was observed.

Download full-text PDF

Source
http://dx.doi.org/10.5603/ep.100030DOI Listing

Publication Analysis

Top Keywords

papp-a2 gene
24
free igf-1
16
short stature
16
fragment catalytic
12
catalytic domain
12
domain active
12
active site
12
papp-a2 protein
12
papp-a2
9
analysis papp-a2
8

Similar Publications

Identification of Pappalysin-2 (PAPP-A2), a modulator of Insulin-like Growth Factor-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome.

Clin Nutr

July 2025

Centre de Recherche sur l'Inflammation (CRI), INSERM U1149, Université Paris Cité, 75018 Paris, France; Gastroenterology and Nutritional Support Department, Hôpital Beaujon (AP-HP), Clichy, France. Electronic address:

Background: Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, is indicated to treat short bowel syndrome (SBS) since 2015. It has been shown to reduce parenteral support (PS) in SBS patients, although patients' response is quite heterogeneous. The exact mechanisms of action of GLP-2 on intestinal cells are still poorly understood.

View Article and Find Full Text PDF
Article Synopsis
  • * The study aimed to analyze the PAPP-A2 gene mutations and perform clinical evaluations, including biochemical analysis of GH-IGF-1 axis parameters in patients with idiopathic short stature.
  • * Results showed no pathogenic mutations in the PAPP-A2 gene; however, free IGF-1 levels were found to correlate more closely with height than total IGF-1 levels.
View Article and Find Full Text PDF

Background: Preeclampsia (PE) is a pregnancy-specific hypertensive disorder affecting 2%-8% of pregnancies worldwide. Biomarker(s) for the disorder exists, but while these have excellent negative predictive value, their positive predictive value is poor. Extracellular vesicles released by the placenta into the maternal circulation, syncytiotrophoblast membrane extracellular vesicles (STB-EVs), have been identified as being involved in PE with the potential to act as liquid biopsies.

View Article and Find Full Text PDF
Article Synopsis
  • The GH/IGF axis is crucial for development and aging, involving various proteins and receptors that are tightly regulated, although this regulation isn't fully understood.
  • Recent findings have identified mutations in the gene for the PAPP-A2 protease, which plays a key role in releasing IGFs from binding proteins to enable their action on IGF receptor 1.
  • This review discusses the effects of PAPP-A2 on growth physiology, drawing insights from studies on genetically modified animals and patients lacking PAPP-A2.
View Article and Find Full Text PDF

Background: Lactation results in substantial maternal bone loss that is recovered following weaning. However, the mechanisms underlying this recovery, and in particular the role of insulin-like growth factor 1 (IGF-I), is not clear. Furthermore, there is little data regarding whether recovery is affected by advanced maternal age.

View Article and Find Full Text PDF